Page last updated: 2024-10-30

metformin and Fungal Diseases

metformin has been researched along with Fungal Diseases in 6 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

Excerpt	Relevance	Reference
"Titrated canagliflozin significantly improved HbA1c, FPG, body weight and SBP, and was generally well tolerated over 26 weeks in patients with T2DM as add-on to metformin and sitagliptin."	5.22	Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. ( Aggarwal, N; Alba, M; Cao, A; Fung, A; Pfeifer, M; Rodbard, HW; Seufert, J, 2016)
"Canagliflozin improved glycaemic control, reduced body weight and systolic blood pressure, and was generally well tolerated in patients aged 55-80 years with T2DM over 104 weeks."	5.20	Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. ( Bode, B; Fung, A; Harris, S; Meininger, G; Stenlöf, K; Sullivan, D; Usiskin, K, 2015)
"Ertugliflozin (1-25 mg/day) improved glycaemic control, body weight and blood pressure in patients with T2DM suboptimally controlled on metformin, and was well tolerated."	5.20	Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. ( Amin, NB; Jain, SM; Lee, DS; Nucci, G; Rusnak, JM; Wang, X, 2015)

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	6 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gallo, S	1
Charbonnel, B	1
Goldman, A	1
Shi, H	1
Huyck, S	1
Darekar, A	1
Lauring, B	1
Terra, SG	1
Bode, B	1
Stenlöf, K	1
Harris, S	1
Sullivan, D	1
Fung, A	2
Usiskin, K	1
Meininger, G	1
Refat, MS	2
Al-Azab, FM	1
Al-Maydama, HM	1
Amin, RR	1
Jamil, YM	1
Kobeasy, MI	1
Amin, NB	1
Wang, X	1
Jain, SM	1
Lee, DS	1
Nucci, G	1
Rusnak, JM	1
Adam, AM	1
Sharshar, T	1
Mohamed, MA	1
Ibrahim, OB	1
Rodbard, HW	1
Seufert, J	1
Aggarwal, N	1
Cao, A	1
Pfeifer, M	1
Alba, M	1

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monothe[NCT02033889]	Phase 3	621 participants (Actual)	Interventional	2013-12-13	Completed
A 12-Week, Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With T[NCT01059825]	Phase 2	375 participants (Actual)	Interventional	2010-02-24	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 104 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

Intervention	Percent A1C (Mean)
Placebo/Glimepiride	-0.58
Ertugliflozin 5 mg	-0.60
Ertugliflozin 15 mg	-0.89

Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

Intervention	Percent A1C (Least Squares Mean)
Placebo/Glimepiride	-0.03
Ertugliflozin 5 mg	-0.73
Ertugliflozin 15 mg	-0.91

Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 52 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

Intervention	Percent A1C (Mean)
Placebo/Glimepiride	-0.68
Ertugliflozin 5 mg	-0.72
Ertugliflozin 15 mg	-0.96

Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 104 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

Intervention	Kilograms (Mean)
Placebo/Glimepiride	-0.18
Ertugliflozin 5 mg	-3.77
Ertugliflozin 15 mg	-3.63

Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

Intervention	Kilograms (Least Squares Mean)
Placebo/Glimepiride	-1.33
Ertugliflozin 5 mg	-3.01
Ertugliflozin 15 mg	-2.93

Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)

The change in body weight from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

Intervention	Kilograms (Mean)
Placebo/Glimepiride	0.07
Ertugliflozin 5 mg	-3.23
Ertugliflozin 15 mg	-3.35

Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 104 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 104 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

Intervention	mg/dL (Mean)
Placebo/Glimepiride	-10.9
Ertugliflozin 5 mg	-18.2
Ertugliflozin 15 mg	-28.2

Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

Intervention	mg/dL (Least Squares Mean)
Placebo/Glimepiride	-0.85
Ertugliflozin 5 mg	-27.54
Ertugliflozin 15 mg	-39.10

Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

Intervention	mg/dL (Mean)
Placebo/Glimepiride	-12.0
Ertugliflozin 5 mg	-22.4
Ertugliflozin 15 mg	-35.2

Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)

This change from baseline reflects the Week 104 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

Intervention	mmHg (Mean)
Placebo/Glimepiride	-0.46
Ertugliflozin 5 mg	-2.36
Ertugliflozin 15 mg	-1.52

Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)

This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

Intervention	mmHg (Least Squares Mean)
Placebo/Glimepiride	0.23
Ertugliflozin 5 mg	-1.59
Ertugliflozin 15 mg	-2.19

Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)

This change from baseline reflects the Week 52 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

Intervention	mmHg (Mean)
Placebo/Glimepiride	0.38
Ertugliflozin 5 mg	-1.40
Ertugliflozin 15 mg	-1.19

Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)

This change from baseline reflects the Week 104 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104

Intervention	mmHg (Mean)
Placebo/Glimepiride	0.05
Ertugliflozin 5 mg	-3.61
Ertugliflozin 15 mg	-3.13

Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)

This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26

Intervention	mmHg (Least Squares Mean)
Placebo/Glimepiride	-0.70
Ertugliflozin 5 mg	-4.38
Ertugliflozin 15 mg	-5.20

Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)

This change from baseline reflects the Week 52 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52

Intervention	mmHg (Mean)
Placebo/Glimepiride	0.65
Ertugliflozin 5 mg	-2.63
Ertugliflozin 15 mg	-4.28

Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

Intervention	Percent change (Least Squares Mean)
Placebo/Glimepiride	-1.23
Ertugliflozin 5 mg	-1.11
Ertugliflozin 15 mg	-0.96

Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

Intervention	Percent change (Least Squares Mean)
Placebo/Glimepiride	0.09
Ertugliflozin 5 mg	-0.19
Ertugliflozin 15 mg	-0.13

Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

BMD at the total hip was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

Intervention	Percent change (Least Squares Mean)
Placebo/Glimepiride	-1.18
Ertugliflozin 5 mg	-1.72
Ertugliflozin 15 mg	-2.02

Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

BMD at the distal forearm was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

Intervention	Percent change (Least Squares Mean)
Placebo/Glimepiride	0.06
Ertugliflozin 5 mg	-0.15
Ertugliflozin 15 mg	-0.13

Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

Intervention	Percent change (Least Squares Mean)
Placebo/Glimepiride	-0.40
Ertugliflozin 5 mg	-0.10
Ertugliflozin 15 mg	0.30

Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

Intervention	Percentage change (Least Squares Mean)
Placebo/Glimepiride	0.22
Ertugliflozin 5 mg	-0.01
Ertugliflozin 15 mg	0.12

Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

BMD at the total hip was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

Intervention	Percent change (Least Squares Mean)
Placebo/Glimepiride	-0.63
Ertugliflozin 5 mg	-0.55
Ertugliflozin 15 mg	-0.36

Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

BMD at the distal forearm was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

Intervention	Percent change (Least Squares Mean)
Placebo/Glimepiride	-0.44
Ertugliflozin 5 mg	-0.59
Ertugliflozin 15 mg	-0.39

Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)

BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

Intervention	Percent change (Least Squares Mean)
Placebo/Glimepiride	-0.69
Ertugliflozin 5 mg	-0.49
Ertugliflozin 15 mg	-0.44

Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)

Intervention	Percent change (Least Squares Mean)
Placebo/Glimepiride	-0.10
Ertugliflozin 5 mg	-0.28
Ertugliflozin 15 mg	0.07

Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)

BMD at the total hip was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52

Intervention	Percent change (Least Squares Mean)
Placebo/Glimepiride	-0.82
Ertugliflozin 5 mg	-1.04
Ertugliflozin 15 mg	-1.32

Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)

CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

Intervention	Percent change (Mean)
Placebo/Glimepiride	10.8
Ertugliflozin 5 mg	51.9
Ertugliflozin 15 mg	80.2

Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)

Intervention	Percent change (Mean)
Placebo/Glimepiride	19.29
Ertugliflozin 5 mg	26.94
Ertugliflozin 15 mg	32.53

Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)

Intervention	Percent change (Mean)
Placebo/Glimepiride	15.54
Ertugliflozin 5 mg	34.36
Ertugliflozin 15 mg	41.57

Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)

P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

Intervention	Percent change (Mean)
Placebo/Glimepiride	19.38
Ertugliflozin 5 mg	10.11
Ertugliflozin 15 mg	24.21

Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)

Intervention	Percent Change (Mean)
Placebo/Glimepiride	24.50
Ertugliflozin 5 mg	8.41
Ertugliflozin 15 mg	19.79

Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)

PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26

Intervention	Percent change (Mean)
Placebo/Glimepiride	-0.98
Ertugliflozin 5 mg	0.28
Ertugliflozin 15 mg	0.14

Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)

Intervention	Percent change (Mean)
Placebo/Glimepiride	0.5
Ertugliflozin 5 mg	0.8
Ertugliflozin 15 mg	0.5

Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)

Intervention	Percent change (Mean)
Placebo/Glimepiride	10.12
Ertugliflozin 5 mg	8.16
Ertugliflozin 15 mg	5.46

Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)

Intervention	Percent Change (Mean)
Placebo/Glimepiride	8.11
Ertugliflozin 5 mg	11.09
Ertugliflozin 15 mg	2.48

Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)

BMD at the distal forearm was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104

Intervention	Percent change (Least Squares Mean)
Placebo/Glimepiride	-0.58
Ertugliflozin 5 mg	-0.40
Ertugliflozin 15 mg	-0.64

Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 104

Intervention	Percentage of Participants (Number)
Placebo/Glimepiride	2.4
Ertugliflozin 5 mg	3.4
Ertugliflozin 15 mg	3.9

Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)

Intervention	Percentage of Participants (Number)
Placebo/Glimepiride	77.5
Ertugliflozin 5 mg	70.5
Ertugliflozin 15 mg	75.6

Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104

Per protocol participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 104

Intervention	Percentage of participants (Number)
Placebo/Glimepiride	24.4
Ertugliflozin 5 mg	11.1
Ertugliflozin 15 mg	10.7

Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26

Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 26

Intervention	Percentage of Participants (Number)
Placebo/Glimepiride	17.7
Ertugliflozin 5 mg	2.9
Ertugliflozin 15 mg	1.5

Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52

Intervention	Percentage of Participants (Number)
Placebo/Glimepiride	17.2
Ertugliflozin 5 mg	4.3
Ertugliflozin 15 mg	1.5

Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 104

Intervention	Percentage of Participants (Number)
Placebo/Glimepiride	7.2
Ertugliflozin 5 mg	10.6
Ertugliflozin 15 mg	12.2

Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 26

Intervention	Percentage of Participants (Number)
Placebo/Glimepiride	2.9
Ertugliflozin 5 mg	8.7
Ertugliflozin 15 mg	12.2

Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)

Intervention	Percentage of Participants (Number)
Placebo/Glimepiride	11.0
Ertugliflozin 5 mg	10.6
Ertugliflozin 15 mg	14.6

Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)

Intervention	Percentage of Participants (Number)
Placebo/Glimepiride	19.1
Ertugliflozin 5 mg	24.6
Ertugliflozin 15 mg	33.7

Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)

Intervention	Percentage of Participants (Number)
Placebo/Glimepiride	15.8
Ertugliflozin 5 mg	35.3
Ertugliflozin 15 mg	40.0

Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)

Intervention	Percentage of Participants (Number)
Placebo/Glimepiride	30.6
Ertugliflozin 5 mg	34.8
Ertugliflozin 15 mg	36.6

Time to Glycemic Rescue Therapy at Week 26

Intervention	Days (Median)
Placebo/Glimepiride	105
Ertugliflozin 5 mg	112
Ertugliflozin 15 mg	139

Ertugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)

Pharmacokinetic samples were collected at approximately 24 hours following the prior day's dose and before administration of the current day's dose. The lower limit of quantitation (LLOQ) was 0.500 mg/mL. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Pre-dose and/or 60 minutes post-dose on Weeks 6, 12, 18, and 30

Intervention	ng/mL (Mean)
	Week 6:Pre-dose	Week 12:Pre-dose	Week 12:60 mins post-dose	Week 18:Pre-dose	Week 18:60 mins post-dose	Week 30:Pre-dose
Ertugliflozin 15 mg	38.38	29.23	228.13	24.46	214.96	30.55
Ertugliflozin 5 mg	14.89	12.34	74.84	9.91	74.39	12.66
Placebo/Glimepiride	NA	NA	NA	0.01	0.01	0.15

Baseline Body Weight

(NCT01059825)
Timeframe: Baseline

Intervention	kg (Mean)
Placebo	83.78
Ertugliflozin 1 mg	83.44
Ertugliflozin 5 mg	85.74
Ertugliflozin 10 mg	82.28
Ertugliflozin 25 mg	81.81
Sitagliptin 100 mg	85.52

Baseline Diastolic Blood Pressure

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. (NCT01059825)
Timeframe: Baseline

Intervention	mmHg (Mean)
Placebo	79.14
Ertugliflozin 1 mg	78.95
Ertugliflozin 5 mg	78.19
Ertugliflozin 10 mg	78.45
Ertugliflozin 25 mg	78.61
Sitagliptin 100 mg	79.15

Baseline Fasting Plasma Glucose

Laboratory measurements were performed after an overnight fast ≥8 hours in duration. (NCT01059825)
Timeframe: Baseline

Intervention	mg/dL (Mean)
Placebo	165.3
Ertugliflozin 1 mg	162.5
Ertugliflozin 5 mg	156.5
Ertugliflozin 10 mg	163.3
Ertugliflozin 25 mg	171.3
Sitagliptin 100 mg	166.2

Baseline Hemoglobin A1c (HbA1c)

HbA1c is measured as percent. (NCT01059825)
Timeframe: Baseline

Intervention	Percent (Mean)
Placebo	8.08
Ertugliflozin 1 mg	8.01
Ertugliflozin 5 mg	7.88
Ertugliflozin 10 mg	8.13
Ertugliflozin 25 mg	8.30
Sitagliptin 100 mg	8.24

Baseline Systolic Blood Pressure

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. (NCT01059825)
Timeframe: Baseline

Intervention	mmHg (Mean)
Placebo	126.7
Ertugliflozin 1 mg	126.5
Ertugliflozin 5 mg	127.9
Ertugliflozin 10 mg	125.8
Ertugliflozin 25 mg	124.9
Sitagliptin 100 mg	126.6

Change From Baseline in Diastolic Blood Pressure at Week 12

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF). (NCT01059825)
Timeframe: Baseline and Week 12

Intervention	mmHg (Least Squares Mean)
Placebo	0.81
Ertugliflozin 1 mg	-1.12
Ertugliflozin 5 mg	-1.01
Ertugliflozin 10 mg	-3.18
Ertugliflozin 25 mg	-1.83
Sitagliptin 100 mg	1.68

Change From Baseline in Diastolic Blood Pressure at Week 2

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF). (NCT01059825)
Timeframe: Baseline and Week 2

Intervention	mmHg (Least Squares Mean)
Placebo	-0.57
Ertugliflozin 1 mg	-1.25
Ertugliflozin 5 mg	-1.26
Ertugliflozin 10 mg	-1.97
Ertugliflozin 25 mg	-3.01
Sitagliptin 100 mg	0.92

Change From Baseline in Diastolic Blood Pressure at Week 4

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF). (NCT01059825)
Timeframe: Baseline and Week 4

Intervention	mmHg (Least Squares Mean)
Placebo	-0.80
Ertugliflozin 1 mg	-2.47
Ertugliflozin 5 mg	-3.08
Ertugliflozin 10 mg	-2.81
Ertugliflozin 25 mg	-2.10
Sitagliptin 100 mg	-0.51

Change From Baseline in Diastolic Blood Pressure at Week 8

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF). (NCT01059825)
Timeframe: Baseline and Week 8

Intervention	mmHg (Least Squares Mean)
Placebo	0.80
Ertugliflozin 1 mg	-1.40
Ertugliflozin 5 mg	-0.69
Ertugliflozin 10 mg	-2.23
Ertugliflozin 25 mg	-1.20
Sitagliptin 100 mg	0.32

Change From Baseline in Fasting Plasma Glucose at Week 12

The change from baseline is the Week 12 FPG minus the Week 0 fasting plasma glucose (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration. (NCT01059825)
Timeframe: Baseline and Week 12

Intervention	mg/dL (Least Squares Mean)
Placebo	2.76
Ertugliflozin 1 mg	-18.23
Ertugliflozin 5 mg	-23.06
Ertugliflozin 10 mg	-31.47
Ertugliflozin 25 mg	-29.26
Sitagliptin 100 mg	-17.29

Change From Baseline in Fasting Plasma Glucose at Week 2

The change from baseline is the Week 2 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration. (NCT01059825)
Timeframe: Baseline and Week 2

Intervention	mg/dL (Least Squares Mean)
Placebo	5.89
Ertugliflozin 1 mg	-15.07
Ertugliflozin 5 mg	-15.68
Ertugliflozin 10 mg	-26.65
Ertugliflozin 25 mg	-16.44
Sitagliptin 100 mg	-14.69

Change From Baseline in Fasting Plasma Glucose at Week 4

The change from baseline is the Week 4 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration. (NCT01059825)
Timeframe: Baseline and Week 4

Intervention	mg/dL (Least Squares Mean)
Placebo	5.17
Ertugliflozin 1 mg	-16.91
Ertugliflozin 5 mg	-22.77
Ertugliflozin 10 mg	-27.95
Ertugliflozin 25 mg	-26.62
Sitagliptin 100 mg	-18.00

Change From Baseline in Fasting Plasma Glucose at Week 8

The change from baseline is the Week 8 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration. (NCT01059825)
Timeframe: Baseline and Week 8

Intervention	mg/dL (Least Squares Mean)
Placebo	3.82
Ertugliflozin 1 mg	-18.25
Ertugliflozin 5 mg	-24.69
Ertugliflozin 10 mg	-31.59
Ertugliflozin 25 mg	-30.99
Sitagliptin 100 mg	-18.93

Change From Baseline in HbA1c at Week 12

HbA1c is measured as percent. The change from baseline is the Week 12 HbA1c percent minus the Week 0 HbA1c percent (last observation carried forward [LOCF]). (NCT01059825)
Timeframe: Baseline and Week 12

Intervention	Percent (Least Squares Mean)
Placebo	-0.11
Ertugliflozin 1 mg	-0.56
Ertugliflozin 5 mg	-0.80
Ertugliflozin 10 mg	-0.73
Ertugliflozin 25 mg	-0.83
Sitagliptin 100 mg	-0.87

Change From Baseline in HbA1C at Week 2

HbA1c is measured as percent. The change from baseline is the Week 2 HbA1c percent minus the Week 0 HbA1c percent (LOCF). (NCT01059825)
Timeframe: Baseline and Week 2

Intervention	Percent (Least Squares Mean)
Placebo	0.00
Ertugliflozin 1 mg	-0.14
Ertugliflozin 5 mg	-0.29
Ertugliflozin 10 mg	-0.22
Ertugliflozin 25 mg	-0.17
Sitagliptin 100 mg	-0.26

Change From Baseline in HbA1c at Week 4

HbA1c is measured as percent. The change from baseline is the Week 4 HbA1c percent minus the Week 0 HbA1c percent (LOCF). (NCT01059825)
Timeframe: Baseline and Week 4

Intervention	Percent (Least Squares Mean)
Placebo	-0.04
Ertugliflozin 1 mg	-0.40
Ertugliflozin 5 mg	-0.49
Ertugliflozin 10 mg	-0.48
Ertugliflozin 25 mg	-0.40
Sitagliptin 100 mg	-0.48

Change From Baseline in HbA1c at Week 8

HbA1c is measured as percent. The change from baseline is the Week 8 HbA1c percent minus the Week 0 HbA1c percent (LOCF). (NCT01059825)
Timeframe: Baseline and Week 8

Intervention	Percent (Least Squares Mean)
Placebo	-0.10
Ertugliflozin 1 mg	-0.57
Ertugliflozin 5 mg	-0.76
Ertugliflozin 10 mg	-0.73
Ertugliflozin 25 mg	-0.75
Sitagliptin 100 mg	-0.77

Change From Baseline in Systolic Blood Pressure at Week 12

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF). (NCT01059825)
Timeframe: Baseline and Week 12

Intervention	mmHg (Least Squares Mean)
Placebo	-0.55
Ertugliflozin 1 mg	-2.69
Ertugliflozin 5 mg	-4.03
Ertugliflozin 10 mg	-3.43
Ertugliflozin 25 mg	-3.93
Sitagliptin 100 mg	-1.09

Change From Baseline in Systolic Blood Pressure at Week 2

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF). (NCT01059825)
Timeframe: Baseline and Week 2

Intervention	mmHg (Least Squares Mean)
Placebo	-1.93
Ertugliflozin 1 mg	-2.30
Ertugliflozin 5 mg	-4.73
Ertugliflozin 10 mg	-2.28
Ertugliflozin 25 mg	-5.39
Sitagliptin 100 mg	-0.91

Change From Baseline in Systolic Blood Pressure at Week 4

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF). (NCT01059825)
Timeframe: Baseline and Week 4

Intervention	mmHg (Least Squares Mean)
Placebo	-2.57
Ertugliflozin 1 mg	-3.94
Ertugliflozin 5 mg	-5.15
Ertugliflozin 10 mg	-5.43
Ertugliflozin 25 mg	-3.33
Sitagliptin 100 mg	-3.32

Change From Baseline in Systolic Blood Pressure at Week 8

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF). (NCT01059825)
Timeframe: Baseline and Week 8

Intervention	mmHg (Least Squares Mean)
Placebo	-0.44
Ertugliflozin 1 mg	-1.53
Ertugliflozin 5 mg	-2.85
Ertugliflozin 10 mg	-3.04
Ertugliflozin 25 mg	-3.30
Sitagliptin 100 mg	-2.43

Number of Participants Who Discontinued Study Medication Due to an AE

An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin and excludes a temporary discontinuation of study medication. (NCT01059825)
Timeframe: Up to 84 days

Intervention	Participants (Number)
Placebo	1
Ertugliflozin 1 mg	1
Ertugliflozin 5 mg	3
Ertugliflozin 10 mg	2
Ertugliflozin 25 mg	1
Sitagliptin 100 mg	1
Metformin Run-in	3

Number of Participants Who Experienced an Advere Event (AE)

Intervention	Participants (Number)
Placebo	29
Ertugliflozin 1 mg	31
Ertugliflozin 5 mg	30
Ertugliflozin 10 mg	29
Ertugliflozin 25 mg	28
Sitagliptin 100 mg	30
Metformin Run-in	82

Percent Change From Baseline in Body Weight at Week 12

The percent change from baseline is the ([Week 12 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF). (NCT01059825)
Timeframe: Baseline and Week 12

Intervention	Percent change (Least Squares Mean)
Placebo	-0.75
Ertugliflozin 1 mg	-1.90
Ertugliflozin 5 mg	-2.50
Ertugliflozin 10 mg	-2.90
Ertugliflozin 25 mg	-2.66
Sitagliptin 100 mg	-0.30

Percent Change From Baseline in Body Weight at Week 2

The percent change from baseline is the ([Week 2 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF). (NCT01059825)
Timeframe: Baseline and Week 2

Intervention	Percent change (Least Squares Mean)
Placebo	-0.24
Ertugliflozin 1 mg	-0.65
Ertugliflozin 5 mg	-1.36
Ertugliflozin 10 mg	-1.14
Ertugliflozin 25 mg	-1.11
Sitagliptin 100 mg	0.21

Percent Change From Baseline in Body Weight at Week 4

The percent change from baseline is the ([Week 4 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF). (NCT01059825)
Timeframe: Baseline and Week 4

Intervention	Percent change (Least Squares Mean)
Placebo	-0.44
Ertugliflozin 1 mg	-1.20
Ertugliflozin 5 mg	-1.76
Ertugliflozin 10 mg	-1.68
Ertugliflozin 25 mg	-1.52
Sitagliptin 100 mg	0.01

Percent Change From Baseline in Body Weight at Week 8

The percent change from baseline is the ([Week 8 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF). (NCT01059825)
Timeframe: Baseline and Week 8

Intervention	Percent change (Least Squares Mean)
Placebo	-0.62
Ertugliflozin 1 mg	-1.65
Ertugliflozin 5 mg	-2.18
Ertugliflozin 10 mg	-2.30
Ertugliflozin 25 mg	-2.40
Sitagliptin 100 mg	-0.38

Percentage of Participants Achieving HbA1C <6.5% at Week 12

Laboratory measurements were performed after an overnight fast ≥8 hours in duration. (NCT01059825)
Timeframe: Week 12

Intervention	Percentage of participants (Number)
Placebo	6.7
Ertugliflozin 1 mg	12.0
Ertugliflozin 5 mg	20.4
Ertugliflozin 10 mg	13.6
Ertugliflozin 25 mg	14.9
Sitagliptin 100 mg	25.5

Percentage of Participants Achieving HbA1c <7% at Week 12

Laboratory measurements were performed after an overnight fast ≥8 hours in duration. (NCT01059825)
Timeframe: Week 12

Intervention	Percentage of participants (Number)
Placebo	15.6
Ertugliflozin 1 mg	44.0
Ertugliflozin 5 mg	42.9
Ertugliflozin 10 mg	38.6
Ertugliflozin 25 mg	36.2
Sitagliptin 100 mg	43.1

Trials

4 trials available for metformin and Fungal Diseases

Article	Year
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4 Topics: Aged; Blood Glucose; Bone Density; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type	2019
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:3 Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL	2015
Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:6 Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Bridged Bicyclo Compounds, Heterocyclic; Di	2015
Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:8 Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-B	2016

Other Studies

2 other studies available for metformin and Fungal Diseases

Article	Year
Synthesis, spectroscopic and antimicrobial studies of La(III), Ce(III), Sm(III) and Y(III) Metformin HCl chelates. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2015, May-05, Volume: 142 Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Chelating Agents; Coordination Complexes; Fun	2015
Study of chemical bonding, physical and biological effect of metformin drug as an organized medicine for diabetes patients with chromium(III) and vanadium(IV) ions. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2015, Volume: 149 Topics: Anti-Infective Agents; Bacterial Infections; Chromium; Coordination Complexes; Fungi; Humans; Metfor	2015